CHEMM Stock Analysis: ChemoMetec | CO
Medical Devices | CO, Denmark | Market Cap: 9.448m DKK | 12M Return: -13.9% | DK0060055861 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 34.3M
EPS Trend: 53.1%
Qual. Beats: 0
Rev. Trend: 68.4%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ChemoMetec A/S (CHEMM) is a Danish life sciences tools company that develops, manufactures, and sells analytical equipment for cell counting and analysis. Founded in 1997 and headquartered in Allerød, Denmark, the company sells its products in the United States, Canada, Europe, and other international markets. Its core offerings include the NucleoCounter line of image cytometers and cell analyzers (NC-3000, NC-250, NC-202, NC-200, NC-203), the SP-100 sperm cell counter for animal reproduction, and the XcytoMatic 40 analyzer for cell density and viability. The company also sells consumables such as cassettes, reagents, lysis buffers, and slides, alongside accessories, software, service and validation plans, and training. It serves customers across cell and gene therapy, cancer and stem cell research, pharmaceutical development and manufacturing, and production quality control in industries such as animal semen, milk, and beer. The firm is also developing next-generation products including the XcytoMatic 30 and Xcyto 5.
ChemoMetec operates in the Life Sciences Tools & Services sub-industry, a segment characterized by specialized instruments, reagents, and consumables sold to research institutions, biopharma companies, and industrial customers. A key feature of its business model is a recurring revenue stream from consumables (cassettes, reagents, and slides) that are used with its installed base of instruments, complementing the higher-margin upfront equipment sales.
- Cell and gene therapy demand fuels instrument sales
- Consumables revenue grows as installed base expands
- US geographic expansion accelerates top-line growth
| Net Income: 201.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA -0.30 > 1.0 |
| NWC/Revenue: 77.60% < 20% (prev 79.94%; Δ -2.35% < -1%) |
| CFO/TA 0.24 > 3% & CFO 210.4m > Net Income 201.8m |
| Net Debt (-285.9m) to EBITDA (267.8m): -1.07 < 3 |
| Current Ratio: 4.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.4m) vs 12m ago 0.06% < -2% |
| Gross Margin: 64.30% > 18% (prev 93.93%; Δ -29.63% > 0.5%) |
| Asset Turnover: 60.52% > 50% (prev 59.85%; Δ 0.67% > 0%) |
| Interest Coverage Ratio: 147.7 > 6 (EBIT TTM 252.9m / Interest Expense TTM 1.71m) |
| A: 0.46 (Total Current Assets 524.8m - Total Current Liabilities 128.2m) / Total Assets 860.9m |
| B: 0.85 (Retained Earnings 733.0m / Total Assets 860.9m) |
| C: 0.30 (EBIT TTM 252.9m / Avg Total Assets 844.5m) |
| D: 5.35 (Book Value of Equity 725.4m / Total Liabilities 135.5m) |
| Altman-Z'' = 13.43 = AAA |
| DSRI: 1.21 (Receivables 99.2m/79.6m, Revenue 511.1m/495.6m) |
| GMI: 1.46 (GM 93.93% / 64.30%) |
| AQI: 1.19 (AQ_t 0.24 / AQ_t-1 0.20) |
| SGI: 1.03 (Revenue 511.1m / 495.6m) |
| TATA: -0.01 (NI 201.8m - CFO 210.4m) / TA 860.9m) |
| Beneish M = -2.30 (Cap -4..+1) = BBB |
As of October 10, 2026, the stock is trading at DKK 586.50 with a total of 60,052 shares traded. Over the past week, the price has changed by +6.54%, over one month by +13.88%, over three months by +43.19% and over the past year by -13.88%.
Current recommended Stop Loss: 561.40 (which is 4.3% or 1.1 ATR below the current price).
ChemoMetec has no consensus analysts rating.
P/E Trailing = 47.5389
P/S = 18.4871
P/B = 12.2475
Revenue TTM = 511.1m DKK
EBIT TTM = 252.9m DKK
EBITDA TTM = 267.8m DKK
Long Term Debt = 2.06m DKK (estimated: total debt 4.59m - short term 2.53m)
Short Term Debt = 2.53m DKK (from shortTermDebt, last quarter)
Debt = 7.65m DKK (from shortLongTermDebtTotal, last quarter) + Leases 3.06m
Net Debt = -285.9m DKK (calculated: Debt 7.65m - CCE 293.6m)
Enterprise Value = 9.16b DKK (9.45b + Debt 7.65m - CCE 293.6m)
Interest Coverage Ratio = 147.7 (Ebit TTM 252.9m / Interest Expense TTM 1.71m)
EV/FCF = 50.33x (Enterprise Value 9.16b / FCF TTM 182.0m)
FCF Yield = 1.99% (FCF TTM 182.0m / Enterprise Value 9.16b)
FCF Margin = 35.62% (FCF TTM 182.0m / Revenue TTM 511.1m)
Net Margin = 39.49% (Net Income TTM 201.8m / Revenue TTM 511.1m)
Gross Margin = 64.30% ((Revenue TTM 511.1m - Cost of Revenue TTM 182.4m) / Revenue TTM)
Gross Margin QoQ = 63.99% (prev 64.64%)
Tobins Q-Ratio = 10.64 (Enterprise Value 9.16b / Total Assets 860.9m)
Interest Expense / Debt = 22.38% (Interest Expense 1.71m / Debt 7.65m)
Taxrate = 21.82% (56.3m / 258.2m)
NOPAT = 197.7m (EBIT 252.9m * (1 - 21.82%))
Current Ratio = 4.09 (Total Current Assets 524.8m / Total Current Liabilities 128.2m)
Debt / Equity = 0.01 (Debt 7.65m / totalStockholderEquity, last quarter 725.4m)
Debt / EBITDA = -1.07 (Net Debt -285.9m / EBITDA 267.8m)
Debt / FCF = -1.57 (Net Debt -285.9m / FCF TTM 182.0m)
Total Stockholder Equity = 662.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 23.90% (Net Income 201.8m / Total Assets 860.9m)
RoE = 30.47% (Net Income TTM 201.8m / Total Stockholder Equity 662.3m)
RoCE = 38.07% (EBIT 252.9m / Capital Employed (Equity 662.3m + L.T.Debt 2.06m))
RoIC = 27.87% (NOPAT 197.7m / Invested Capital 709.6m)
WACC = 8.86% (E(9.45b)/V(9.46b) * Re(8.85%) + D(7.65m)/V(9.46b) * Rd(22.38%) * (1-Tc(0.22)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -38.12 | Cagr: -0.04%
[DCF] Terminal Value 74.02% ; FCFF base≈180.3m ; Y1≈184.8m ; Y5≈204.0m
[DCF] Fair Price = 186.1 (EV 2.91b - Net Debt -285.9m = Equity 3.19b / Shares 17.2m; r=8.86% [WACC]; 5y FCF grow 2.51% → 2.50% )
EPS Correlation: 53.09 | EPS CAGR: 10.76% | SUE: 0.79 | # QB: 0
Revenue Correlation: 68.36 | Revenue CAGR: 13.98% | SUE: -0.04 | # QB: 0
EPS current Quarter (2025-09-30): EPS=3.98 | Chg30d=+5.85% | Revisions=+25% | Analysts=1
EPS next Quarter (2025-12-31): EPS=4.85 | Chg30d=+0.41% | Revisions=+25% | Analysts=1
EPS current Year (2025-06-30): EPS=10.56 | Chg30d=-3.65% | Revisions=-40% | GrowthEPS=+34.9% | GrowthRev=+21.8%
EPS next Year (2026-06-30): EPS=12.91 | Chg30d=+3.20% | Revisions=+25% | GrowthEPS=+6.4% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +12% (up=3, down=2)